# Transcriptomic Profiling Identifies a Distinct Molecular Signature in OSMF-Derived Oral Squamous Cell Carcinoma

**Authors:** Kavitha Prasad, Sowmya Samudrala Venkatesiah, Dominic Augustine, Ananya Anurag Anand, Prashanthi Karyala, Sukeerthi Dasharathy, Roopa S. Rao, Soma Chaki

PMC · DOI: 10.3390/life16030454 · 2026-03-10

## TL;DR

This study finds that oral cancer arising from a fibrotic condition called OSMF has a unique genetic profile compared to regular oral cancer.

## Contribution

The paper identifies a distinct molecular signature in OSMF-derived oral cancer through transcriptomic profiling.

## Key findings

- OSMF-derived OSCC shows upregulated genes related to immune response, proliferation, and metabolism.
- Downregulated genes in OSMF-derived OSCC include those involved in epithelial differentiation and immune regulation.
- Pathway analysis reveals activation of muscle development and embryonic pathways in OSMF-derived OSCC.

## Abstract

Background: Oral Submucous Fibrosis (OSMF) is a significant global oral health problem, particularly prevalent in India, with a high risk of progression to Oral Squamous Cell Carcinoma (OSCC). This study investigates the molecular mechanisms involved in the transformation of OSMF to OSCC using transcriptomic profiling. Methods: High-throughput RNA sequencing was performed on fresh de novo OSCC samples (n = 8) and OSMF derived OSCC using Illumina-compatible NEXTflex Rapid Directional RNA Sequencing. Normalization and differential gene expression analysis were conducted, and genes exhibiting an absolute log2 fold change of ≥2 with a co-variate-adjusted p-value ≤ 0.05 were identified as significant. Results: Upregulated genes were associated with cytokine and immune responses (ABRA, TTTY14, EIF1AY), cellular proliferation and apoptosis (LINC00314, RPS4Y1, SERPINA5, TRIM63, FABP7), and energy metabolism, indicating metabolic adaptations during malignant progression. Pathway analysis showed increased expression of TNNT1, TNNI1, MYL4, and ACTN3, implicating muscle development and embryonic pathways in OSMF transformation. Conversely, genes related to epithelial differentiation and keratinization (FLG, FLG2, HRNR, TCHH, KRT73), immune regulation and tumor suppression (HLA-G, UNC5D), and metabolic signaling were downregulated, reflecting loss of tissue integrity and immune control. Conclusions: OSMF-derived OSCC exhibits a distinct transcriptomic landscape compared with de novo OSCC, characterized by altered epithelial differentiation, immune modulation, and activation of developmental pathways. The observed gene dysregulation findings establish that OSCC developing in the background of OSMF is molecularly distinct from de novo OSCC, underscoring the biological impact of the pre-existing fibrotic milieu on tumor transcriptional architecture.

## Linked entities

- **Genes:** ABRA (actin binding Rho activating protein) [NCBI Gene 137735], TTTY14 (testis expressed transcript, Y-linked 14) [NCBI Gene 83869], EIF1AY (eukaryotic translation initiation factor 1A Y-linked) [NCBI Gene 9086], LINC00314 (long intergenic non-protein coding RNA 314) [NCBI Gene 246705], RPS4Y1 (ribosomal protein S4 Y-linked 1) [NCBI Gene 6192], SERPINA5 (serpin family A member 5) [NCBI Gene 5104], TRIM63 (tripartite motif containing 63) [NCBI Gene 84676], FABP7 (fatty acid binding protein 7) [NCBI Gene 2173], TNNT1 (troponin T1, slow skeletal type) [NCBI Gene 7138], TNNI1 (troponin I1, slow skeletal type) [NCBI Gene 7135], MYL4 (myosin light chain 4) [NCBI Gene 4635], ACTN3 (actinin alpha 3) [NCBI Gene 89], FLG (filaggrin) [NCBI Gene 2312], FLG2 (filaggrin 2) [NCBI Gene 388698], HRNR (hornerin) [NCBI Gene 388697], TCHH (trichohyalin) [NCBI Gene 7062], KRT73 (keratin 73) [NCBI Gene 319101], HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135], UNC5D (unc-5 netrin receptor D) [NCBI Gene 137970]
- **Diseases:** Oral Submucous Fibrosis (MONDO:0018166), Oral Squamous Cell Carcinoma (MONDO:0004958)

## Full-text entities

- **Genes:** TCHH (trichohyalin) [NCBI Gene 7062] {aka THH, THL, TRHY, UHS3}, ACTN3 (actinin alpha 3) [NCBI Gene 89] {aka ACTN3D}, TRIM63 (tripartite motif containing 63) [NCBI Gene 84676] {aka CMH31, IRF, MURF1, MURF2, RNF28, SMRZ}, ABRA (actin binding Rho activating protein) [NCBI Gene 137735] {aka STARS}, MYL4 (myosin light chain 4) [NCBI Gene 4635] {aka ALC1, AMLC, GT1, PRO1957}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, RPS4Y1 (ribosomal protein S4 Y-linked 1) [NCBI Gene 6192] {aka RPS4Y, S4}, KRT73 (keratin 73) [NCBI Gene 319101] {aka CK-73, IRT6IRS3, K6IRS3, K73, KRT6IRS3}, UNC5D (unc-5 netrin receptor D) [NCBI Gene 137970] {aka PRO34692, Unc5h4}, HRNR (hornerin) [NCBI Gene 388697] {aka FLG3, S100A16, S100a18}, FLG2 (filaggrin 2) [NCBI Gene 388698] {aka IFPS, PSS6}, SERPINA5 (serpin family A member 5) [NCBI Gene 5104] {aka PAI-3, PAI3, PCI, PCI-B, PLANH3, PROCI}, TNNI1 (troponin I1, slow skeletal type) [NCBI Gene 7135] {aka SSTNI, TNN1}, TNNT1 (troponin T1, slow skeletal type) [NCBI Gene 7138] {aka ANM, NEM5, STNT, TNT, TNTS}, FLG (filaggrin) [NCBI Gene 2312] {aka ATOD2, FLG-1, FLG1}, TTTY14 (testis expressed transcript, Y-linked 14) [NCBI Gene 83869] {aka CYorf14, NCRNA00137, NCRNA00185, PRO2834, TTY14}, FABP7 (fatty acid binding protein 7) [NCBI Gene 2173] {aka B-FABP, BLBP, FABPB, MRG}, LINC00314 (long intergenic non-protein coding RNA 314) [NCBI Gene 246705] {aka C21orf94, NCRNA00314}, EIF1AY (eukaryotic translation initiation factor 1A Y-linked) [NCBI Gene 9086] {aka eIF-4C}
- **Diseases:** tumor (MESH:D009369), OSCC (MESH:D000077195), OSMF (MESH:D009914)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027735/full.md

---
Source: https://tomesphere.com/paper/PMC13027735